Literature DB >> 19772512

EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria.

T Zuberbier1, R Asero, C Bindslev-Jensen, G Walter Canonica, M K Church, A Giménez-Arnau, C E H Grattan, A Kapp, H F Merk, B Rogala, S Saini, M Sánchez-Borges, P Schmid-Grendelmeier, H Schünemann, P Staubach, G A Vena, B Wedi, M Maurer.   

Abstract

This guideline, together with its sister guideline on the management of urticaria [Zuberbier T, Asero R, Bindslev-Jensen C, Canonica GW, Church MK, Giménez-Arnau AM et al. EAACI/GA(2)LEN/EDF/WAO Guideline: Management of urticaria. Allergy, 2009; 64:1427-1443] is the result of a consensus reached during a panel discussion at the 3rd International Consensus Meeting on Urticaria, Urticaria 2008, a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO). Urticaria is a frequent disease. The life-time prevalence for any subtype of urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria do not only cause a decrease in quality of life, but also affect performance at work and school and, as such, are members of the group of severe allergic diseases. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors, and pathomechanisms. In addition, it outlines evidence-based diagnostic approaches for different subtypes of urticaria. The correct management of urticaria, which is of paramount importance for patients, is very complex and is consequently covered in a separate guideline developed during the same consensus meeting. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19772512     DOI: 10.1111/j.1398-9995.2009.02179.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  128 in total

Review 1.  Chronic urticaria.

Authors:  Torsten Zuberbier
Journal:  Curr Allergy Asthma Rep       Date:  2012-08       Impact factor: 4.806

2.  [Omalizumab for therapy-resistant chronic urticaria with angioedema].

Authors:  H Korkmaz; S Eigelshoven; B Homey
Journal:  Hautarzt       Date:  2010-10       Impact factor: 0.751

3.  [Urticaria. Sometimes IgE-mediated?].

Authors:  D Wieczorek; J Langhorst; A Kapp; B Wedi
Journal:  Hautarzt       Date:  2013-09       Impact factor: 0.751

4.  [Useful tools for documenting urticaria].

Authors:  P Staubach; A Groffik
Journal:  Hautarzt       Date:  2013-09       Impact factor: 0.751

Review 5.  [Diagnosis and therapy of chronic urticaria-what is expected from the revision and update of the international guidelines? A report of the public consensus conference "URTICARIA 2012"].

Authors:  M Maurer; M Magerl; M Metz; T Zuberbier
Journal:  Hautarzt       Date:  2013-09       Impact factor: 0.751

Review 6.  Chronic spontaneous urticaria: an autoimmune disease? A revision of the literature.

Authors:  Gabriele Di Lorenzo; Maria Stefania Leto-Barone; Simona La Piana; Aurelio Seidita; Giovam Battista Rini
Journal:  Clin Exp Med       Date:  2012-05-15       Impact factor: 3.984

Review 7.  The urticarias: pathophysiology and management.

Authors:  Clive Grattan
Journal:  Clin Med (Lond)       Date:  2012-04       Impact factor: 2.659

Review 8.  [Chronic spontaneous urticaria: An autoimmune disease?].

Authors:  M Abajian; M Maurer; N Schoepke
Journal:  Hautarzt       Date:  2013-09       Impact factor: 0.751

Review 9.  Helicobacter pylori and skin autoimmune diseases.

Authors:  Eli Magen; Jorge-Shmuel Delgado
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

10.  ACE-inhibitor induced angio-oedema treated with complement C1-inhibitor concentrate.

Authors:  Eva Rye Rasmussen; Anette Bygum
Journal:  BMJ Case Rep       Date:  2013-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.